RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease

Neoplasia

Volumn 11, Issue 9, 2009, Pages 956-963

  Gust, Kilian M ^a   Hofer, Matthias D ^b   Perner, Sven R ^c   Kim, Robert ^b   Chinnaiyan, Arul M ^d   Varambally, Sooryanarayana ^d   Moller, Peter ^a   Rinnab, Ludwig ^a   Rubin, Mark A ^c   Greiner, Jochen ^a   Schmitt, Michael ^a,e   Kuefer, Rainer ^a   Ringhoffer, Mark ^a  

^a UNIVERSITY OF ULM   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD168 PROTEIN; COMPLEMENTARY DNA; ONCOPROTEIN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CELL COUNT; CELL VIABILITY; CHRONIC LEUKEMIA; CONTROLLED STUDY; DATA MINING; DNA MICROARRAY; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; MALE; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RHAMM GENE; SEROLOGY; TISSUE MICROARRAY; TREATMENT FAILURE;

ANTIGENS, CD44; ANTIGENS, NEOPLASM; APOPTOSIS; CELL PROLIFERATION; DATABASES, FACTUAL; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 69249106813     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09694     Document Type: Article

References (60)

1. Horwich A and Parker C (2007). Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 18 (Suppl 2), ii36-ii37.
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, and Edwards BK (2003). Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95, 1276-1299.
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, and Thun MJ (2004). Cancer statistics, 2004. CA Cancer J Clin 54, 8-29.
4. Namiki K and Rosser CJ (2007). Neoadjuvant therapy and prostate cancer: what a urologist should know. Curr Opin Urol 17, 188-193.
5. Graham J (2005). Chemotherapy for metastatic disease: current status. Clin Oncol (R Coll Radiol) 17, 572-578.
6. Hadaschik BA, Sowery RD, and Gleave ME (2007). Novel targets and approaches in advanced prostate cancer. Curr Opin Urol 17, 182-187.
7. Armstrong AJ and George DJ (2007). Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. Ther Clin Risk Manag 3, 877-883.
8. Kerr C (2007). Satraplatin for hormone-refractory prostate cancer. Lancet Oncol 8, 290.
9. McKeage MJ (2007). Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. Drugs 67, 859-869.
10. Sternberg CN (2005). Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 96, 990-994.
11. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, et al. (2005). Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68, 2-9.
12. Kuefer R, Genze F, Zugmaier W, Hautmann RE, Rinnab L, Gschwend JE, Angelmeier M, Estrada A, and Buechele B (2007). Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer. Neoplasia 9, 246-253.
13. Chen JS, Faller DV, and Spanjaard RA (2003). Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets 3, 219-236.
14. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, and Lilly MB (2007). Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 6, 163-172.
15. Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, et al. (2008). Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 68, 7475-7483.
16. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, et al. (2008). Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26, 5198-5203.
17. Wang M, Tan W, Zhou J, Leow J, Go M, Lee HS, and Casey PJ (2008). A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells. J Biol Chem 283, 18678-18684.
18. Guerin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, and Milano G (2008). Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134, 51-57.
19. Sonpavde G, Hutson TE, Berry WR, Boehm KA, and Asmar L (2008). Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin Genitourin Cancer 6, 134-137.
20. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, and Iacobelli S (2008). Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 270, 229-233.
21. Pantuck AJ, Zomorodian N, and Belldegrun AS (2007). Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Curr Urol Rep 8, 3-4.
22. Bibikova M, Chudin E, Arsanjani A, Zhou L, Garcia EW, Modder J, Kostelec M, Barker D, Downs T, Fan JB, et al. (2007). Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 89, 666-672.
23. Chen T, Tang XD, Wan Y, Chen L, Yu ST, Xiong Z, Fang DC, Liang GP, and Yang SM (2008). HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 10, 977-986.
24. Malyankar UM (2007). Tumor-associated antigens and biomarkers in cancer and immune therapy. Int Rev Immunol 26, 223-247.
25. Ambs S, Marincola FM, and Thurin M (2008). Profiling of immune response to guide cancer diagnosis, prognosis, and prediction of therapy. Cancer Res 68, 4031-4033.
26. Dougan M and Dranoff G (2009). Immune therapy for cancer. Annu Rev Immunol 27, 83-117.
27. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, et al. (2005). Autoantibody signatures in prostate cancer. N Engl J Med 353, 1224-1235.
28. Bradford TJ, Wang X, and Chinnaiyan AM (2006). Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 24, 237-242.
29. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G, Heilmann V, Gschwend J, Bergmann L, Dohner H, et al. (2002). Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia - associated antigen in acute and chronic myeloid leukemia. Exp Hematol 30, 1029-1035.
30. Wang C, Thor AD, Moore DH II, Zhao Y, Kerschmann R, Stern R, Watson PH, and Turley EA (1998). The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 4, 567-576.
31. Lin SL, Chang D, Chiang A, and Ying SY (2008). Androgen receptor regulates CD168 expression and signaling in prostate cancer. Carcinogenesis 29, 282-290.
32. Lin SL, Chang D, and Ying SY (2007). Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis 28, 310-320.
33. Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, Yu Y, Gotz M, Heyduk M, Ritter G, et al. (2008). RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111, 1357-1365.
34. Yang XF, Wu CJ, Chen L, Alyea EP, Canning C, Kantoff P, Soiffer RJ, Dranoff G, and Ritz J (2002). CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 62, 5517-5522.
35. Webster WS, Small EJ, Rini BI, and Kwon ED (2005). Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 23, 8262-8269.
36. Manley S, Mucci NR, De Marzo AM, and Rubin MA (2001). Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol 159, 837-843.
37. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, and Pienta KJ (2000). Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6, 1038-1045.
38. Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, and Rubin MA (2006). Prognostic factors in lymph node-positive prostate cancer. Urology 67, 1016-1021.
39. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
40. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. (2005). Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406.
41. Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, and Chinnaiyan AM (2005). Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J 19, 243-245.
42. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. (2007). Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166-180.
43. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, and Chinnaiyan AM (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6.
44. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629.
45. Rubin MA, Dunn R, Strawderman M, and Pienta KJ (2002). Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26, 312-319.
46. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi OP (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4, 844-847.
47. Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami HO, et al. (2005). Decreased α-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 14, 1424-1432.
48. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al. (2004). Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22, 2790-2799.
49. La Tulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, and Gerald WL (2002). Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62, 4499-4506.
50. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, and Pfreundschuh M (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92, 11810-11813.
51. Goransson O, Deak M, Wullschleger S, Morrice NA, Prescott AR, and Alessi DR (2006). Regulation of the polarity kinases PAR-1/MARK by 14-3-3 interaction and phosphorylation. J Cell Sci 119, 4059-4070.
52. Wong LJ, Brunetti-Pierri N, Zhang Q, Yazigi N, Bove KE, Dahms BB, Puchowicz MA, Gonzalez-Gomez I, Schmitt ES, Truong CK, et al. (2007). Mutations in the MPV17 gene are responsible for rapidly progressive liver failure in infancy. Hepatology 46, 1218-1227.
53. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, and Chinnaiyan AM (2004). Humoral immune response to α-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 96, 834-843.
54. + T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 106, 938-945.
55. Hall CL and Turley EA (1995). Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. J Neurooncol 26, 221-229.
56. Greiner J, Bullinger L, Guinn BA, Dohner H, and Schmitt M (2008). Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 14, 7161-7166.
57. + T cell responses. Int J Oncol 34, 629-639.
58. Zlobec I, Terracciano L, Tornillo L, Gunthert U, Vuong T, Jass JR, and Lugli A (2008). Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut 57, 1413-1419.
59. Dunn GP, Old LJ, and Schreiber RD (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148.
60. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, et al. (2006). Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 108, 4109-4117.